GSK, Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a ...

Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...

The 2018-2019 influenza season is one such case. The vaccine’s effectiveness during that year was an abysmal 29%, according ...

Federal officials plan to double the stockpile of emergency bird flu vaccines as they identify more people infected with the ...

The Center for Biomedical Advanced Research and Development Authority (BARDA) is giving $72 million to three drugmakers to ...

The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and ...

There are currently no recommendations for anyone to be vaccinated against bird flu and federal health officials note this is ...

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

Wyoming Attorney General Bridget Hill on Friday announced that a settlement with a French pharmaceutical company will cap the ...

Sanofi (SNY), and CSL (CSLLY) win $72M U.S. contract to expand bird flu vaccine production amid fears of human transmission.

Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential ...

The litigation comes as pharmacy benefit managers Express Scripts, CVS Caremark and Optum Rx have faced growing criticism over their role in high drug costs — including a recent lawsuit from the ...